The eighty-eight subject single and multiple ascending dose trial will test tolerability, safety and pharmacokinetics of the oral dosage form of the drug and will compare its properties to those of Zyvox, the only marketed drug in the oxazolidinone class.
TR-701 is a novel oral and IV oxazolidinone antibiotic with potent activity against drug-resistant gram-positive bacterial pathogens including those resistant to Zyvox.
Jeffrey Stein, president and CEO of Trius Therapeutics, said: “In this early clinical trial our goal is to demonstrate the potential of TR-701 to provide patients and clinicians with more convenient dosing and a broader safety margin than the current standard of care.”